Mohammed Asmal, Ph.D.
Affiliations: | 2002 | Columbia University, New York, NY |
Area:
Molecular Biology, Cell BiologyGoogle:
"Mohammed Asmal"Parents
Sign in to add mentor| Jeremy Luban | grad student | 2002 | Columbia | |
| (Characterization of the Ppia -/- mouse and the identification of a family of ribosomal regulatory proteins in T -helper 2 cells.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Tisdale JF, Pierciey FJ, Bonner M, et al. (2020) Safety and Feasibility of Hematopoietic Progenitor Stem Cell Collection by Mobilization with Plerixafor Followed by Apheresis vs Bone Marrow Harvest in Patients with Sickle Cell Disease in the Multi-center HGB-206 Trial. American Journal of Hematology |
| Hsieh MM, Bonner M, Pierciey FJ, et al. (2020) Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease. Blood Advances. 4: 2058-2063 |
| Bonner M, Kanter J, Macari E, et al. (2019) The Relationships between Target Gene Transduction, Engraftment of HSCs and RBC Physiology in Sickle Cell Disease Gene Therapy Blood. 134: 206-206 |
| Magrin E, Semeraro M, Magnani A, et al. (2019) Results from the Completed Hgb-205 Trial of Lentiglobin for β-Thalassemia and Lentiglobin for Sickle Cell Disease Gene Therapy Blood. 134: 3358-3358 |
| Rasko J, Walters M, Kwiatkowski J, et al. (2019) Efficacy and safety of LentiGlobin gene therapy in patients with transfusion-dependent β-thalassemia and non-β0/β0 genotypes: Updated results from the completed phase 1/2 Northstar and ongoing phase 3 Northstar-2 studies Cytotherapy. 21: S14 |
| Anurathapan U, Locatelli F, Kwiatkowski JL, et al. (2019) Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia: Outcomes from the Phase 1/2 Northstar and Phase 3 Northstar-2 Studies Biology of Blood and Marrow Transplantation. 25: S66-S67 |
| Mapara MY, Tisdale JF, Kanter J, et al. (2019) Lentiglobin Gene Therapy in Patients with Sickle Cell Disease: Updated Interim Results from Hgb-206 Biology of Blood and Marrow Transplantation. 25: S64-S65 |
| Esrick EB, Manis JP, Daley H, et al. (2018) Successful hematopoietic stem cell mobilization and apheresis collection using plerixafor alone in sickle cell patients. Blood Advances. 2: 2505-2512 |
| Thompson AA, Walters MC, Kwiatkowski J, et al. (2018) Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia. The New England Journal of Medicine. 378: 1479-1493 |
| Tisdale JF, Kanter J, Mapara MY, et al. (2018) Current Results of Lentiglobin Gene Therapy in Patients with Severe Sickle Cell Disease Treated Under a Refined Protocol in the Phase 1 Hgb-206 Study Blood. 132: 1026-1026 |